J. Wesson Ashford Curriculum Vitae

CURRICULUM VITAE:  (June 7, 2016)
NAME:  John Wesson Ashford, Jr., M.D., Ph.D. (Wes)

Current Positions: 
Clinical Professor (affiliated), Department of Psychiatry and Behavioral Science, Stanford
Staff Psychiatrist, VA Palo Alto Health Care System
Senior Research Scientist, Stanford / VA Aging Clinical Research and Alzheimer Centers
Director, War Related Illness and Injury Study Center, VA Palo Alto Health Care System

MARITAL STATUS:  Married, 4 children, 6 grandchildren
RESIDENCE:  Redwood City, California 94061

PROFESSIONAL ADDRESS:
    War Related Illness & Injury Study Center
    VA Palo Alto Health Care System
    3801 Miranda Way - 151Y
    Palo Alto, CA 94304-1207
    Tel: (650) 852-3316 (VA War Related Illness & Injury Study Center)
    Fax: (650) 852-3297
    Academic e-mail:
    VA email: 
    Business e-mail:

UNDERGRADUATE EDUCATION
1966 - 1967    Cornell University, Ithaca, New York
1967 - 1970    University of California, Berkeley, B.A. June, 1970
MEDICAL EDUCATION
1970 - 1974    University of California, Los Angeles, M.D. September, 1974
GRADUATE EDUCATION
1970 - 1984    University of California, Los Angeles - Neuroscience
1971                Summer Fellowship in sleep research (Dr. M. Jouvet, Lyon, France)
1974                Teaching Assistant, Basic Neurology for Medical students (Dr. J. Schlag)
1975                Teaching Assistant, Neuroanatomy, Neurophysiology for graduate students (Drs. Scheibel, Decima)
1975                Advanced to Candidacy - Neuroscience
1975 - 1980    On leave of absence for Psychiatric Residency
1979 - 1984    Laboratory of Dr. J. M.  Fuster (Doctoral Committee Chairman) Dissertation signed in March, 1984
June, 1984      Ph.D. awarded in Neuroscience
POSTGRADUATE TRAINING
1975 - 1976   Rotating Psychiatry Internship, UCLA
1976 - 1979   Residency in Psychiatry, UCLA
1978 - 1979   Chief Resident, Geriatric Neuropsychiatry Inpatient Unit, UCLA
1977 - 1979   Resident, Co-founder, UCLA Neurobehavior Clinic
1979 - 1980   Fellowship in Psychiatry, UCLA
1980 - 1981   Fellowship, Mental Health Training Program, UCLA
LICENSURES
1976 - 1986       California State Medical License
2005 - present
1976 - present    DEA License
1981                   Diplomate, American Board of Psychiatry and Neurology (Psychiatry)
1985 - 1992        Illinois State Medical License
1992 - present    Kentucky State Medical License
MEMBERSHIPS
Active
  American Association for Geriatric Psychiatry
          (Program Committee, 2001, 2002, 2003)
          (CME committee, 2002, 2003, 2004, 2005, 2006) 
International Psychogeriatrics Association
          (Program Committee, Membership Committee, 2002, 2003)
American Psychiatric Association
Northern California Psychiatry Society
Society for Brain Mapping and Therapeutics
Society for Neuroscience
          (Past President, Sangamon Chapter, Springfield, Illinois, 1991)

Past
  American Association for the Advancement of Science
Southern Association for Research in Psychiatry
          (Secretary, 1997-1998; organizer of 1998 meeting)
  American Medical Association
  Gerontological Society of America
  International Neuropychological Society

EDITORIAL BOARD
  Journal of Mental Health and Aging (2003-2005)
Clinical Editor, Senior Editor, Journal of Alzheimer’s Disease (2008 – 2012; 2012- present),

JOURNAL REVIEWER (sample from over 30)
Alzheimer’s Disease and Associated Disorders
Alzheimer’s & Dementia
Archives of General Psychiatry
American Journal of Geriatric Psychiatry
JAMA
Journal of Alzheimer’s Disease (Senior Editor)
Life Sciences
Neurology

GRANT/AWARD REVIEWER
NIH Population Sciences and Epidemiology Panel (2013)                                                
NIH Lasker Award Panel (2013)
NIH SBIR (Small Business Innovation Research) Panel (2009 – present)
Alzheimer Association grant applications (2001- present)
State of California, Alzheimer grant applications (2004 - 2008)
VA Office of Research and Development (ad hoc – 2013)
PROFESSIONAL APPOINTMENTS
07/79 - 09/79   Staff Psychiatrist, Atascadero State Hospital
10/79 - 06/80   Associate Director, Geriatric Neuropsychiatry Inpatient Unit, UCLA/NPI
07/80 - 06/85   Director, Geriatric Psychiatry Outpatient Clinic, UCLA/NPI (50% time)
08/84 - 06/85   Research Director, Geriatric Psychiatry Ward, Brentwood VA Hospital (50% time)
09/85 - 12/90   Consultant, Geriatric Psychiatry, Adolf Meyer State Mental Hospital, Illinois
01/91 - 12/92   Staff Psychiatrist, VAMC, Martinez, California
12/92 - 03/03   Staff Psychiatrist, VAMC, Lexington, Kentucky
10/94 - 03/03   Director, Memory Disorders Clinic, VAMC, Lexington
07/00 - 9/01     Acting Chief, Mental Health Service, VAMC, Lexington
03/03 – pres.    Staff Psychiatrist, Palo Alto VA Health Care System, Palo Alto, CA
07/07 – pres.    Director, War Related Illness and Injury Study Center,
VA Palo Alto Health Care System, Palo Alto, CA
ACADEMIC APPOINTMENTS
07/83 - 06/85   Adjunct Lecturer, Department of Psychiatry, UCLA
07/85 - 12/90   Assistant Professor, Department of Psychiatry, Southern Illinois University (Springfield)
01/91 - 12/92   Associate Professor, Department of Psychiatry, University of California, Davis
12/92 - 06/03   Associate Professor, Departments of Psychiatry and
                              Neurology and Sanders Brown Center on Aging, University of Kentucky
06/95                Tenure Granted
12/92 - 6/01     Vice-chair of Research, Department of Psychiatry, University of Kentucky
03/03 - pres.    Senior Research Scientist, Stanford / VA Aging Clinical Research Center
03/05 – 09/09  Associate Professor, Stanford University Department of Psychiatry (abeyed)
09/09 - pres.    Clinical Professor (affiliated), Department of Psychiatry and Behavioral Sciences,
School of Medicine, Stanford University

Committee Memberships
10/09 – pres.    Stanford University – Internal Review Board (IRB)
2003 – 2010.    VA Palo Alto Health Care System – Medication Management Committee
2007 – pres.     VA Palo Alto Health Care System –Informatics Committee

Stanford University, Department of Psychiatry & Behavioral Sciences –
2005 – pres.      Psychiatry Residency Selection Committee
2011 – pres.      Appointment & Promotions Committee – Clinician Educator Faculty Line

HONORS
05/85      Finalist, Lindsley Prize (Best Dissertation in Behavioral Neuroscience), Soc. for Neuroscience
06/90      Teacher of the Year, Southern Illinois University Psychiatry Residency
11/93      Clinical Digest Series--Outstanding Article
                  (Coburn, K.L. Ashford, J.W., and Moreno, M.A., 1993--see publication #31)
03/04-2013    Scientific Advisory Board, Northern California Alzheimer Association
08/06- pres.    Chair, Memory Screening Advisory Board, Alzheimer’s Foundation of America
2008 - pres.   Medical Advisory Board, Alzheimer’s Foundation of America

RESEARCH AWARDS (ACTIVE)
Collaborator with the Stanford / VA Alzheimer Center, supporting role and Principle Local Investigator roles in several on-going and developing projects, including several studies of the NIA funded Alzheimer’s Disease Cooperative Study group and the Alzheimer’s Disease Neuroimaging Initiative.

Principal Investigator: John Wesson Ashford, MD, Project Title: rTMS for the Treatment of Chronic Pain in GW1 Veterans.   VA Merit Award. Award Document Number:  ICX000792A. Project Period: 11/01/2011-10/31/2015.

RESEARCH AWARDS (PAST)

Principal Investigator
11/84 - 06/85   NPI/UCLA Biomedical Research Support Grant: "Influence of Transdermal Nicotine on Memory Performance in Alzheimer's Type Dementia." ($5,000)

08/87 - 12/89   Southern Illinois University Coordinator (5% time): National Institute of Aging (1U01AG06777-01); Alzheimer’s Disease Patient Registry (P.I. J. Brody, University of Illinois, Chicago), $27,525. (revised 5U01AG006777-02, 9/30/86 - 12/31/89 to Dr. Brody and 5U01AG006777-03, 9/30/86 - 12/31/90 to Dr. Donna Cohen).

12/87 - 1/91     R.J. Reynolds Tobacco Company, Inc., "Effect of nicotine on cholinergic
receptors in the brain and on behavior in the monkey": $50,000

01/94 - 06/96   Miles Laboratories: "Study of Metrifonate" Phase II-b (D93-029),$230,000; 20% time

05/94 - 12/96   Miles Laboratories: "Study of Metrifonate" Phase II-bx(D93-029x),$100,000; 10% time

01/94 - 1997   "Haloperidol, Trazodone, and Behavior Management Techniques in Alzheimer's Disease Patients with Disruptive Agitated Behaviors: A Controlled Clinical Trial." Sub-contract from the Alzheimer's Disease Cooperative Studies Group, Leon Thal, P.I., University of California, San Diego, Funded by National Institute of Aging, $63,000; 10% time

07/94 - 6/95   "Wolfe County Alzheimer's Study", Research Development Review Committee, Department of Psychiatry and State Department of Mental Health, $10,000; 5% time

1994 - 1998    Bayer Pharmaceutical: Safety and Efficacy of Metrifonate in Alzheimer Patients

01/96 - 2001   Progressive Deterioration of Cortical Blood Flow by Localized Anatomical Element (LOXEL) Across the Full Spectrum of Deterioration in Alzheimer's Disease. DuPont Pharmaceutical (gift of ECD, Ethylene Cysteinate Dimer)

11/98 - 2002   Olanzapine vs. risperidone and placebo in the treatment of psychosis and associated behavioral disturbances in patients with dementia (funded by Eli Lilly Pharmaceuticals, managed by SCIREX Corp., $107,798)

11/98 - 2002   A randomized evaluation-blind study of olanzapine and valproic acid in the treatment of agitation in Alzheimer's patients (investigator initiated project, funded by Eli Lilly Pharmaceuticals, $160,000, 30 patients, not completed).

Principal Investigator (2002)  Lithium treatment of Alzheimer's disease: Effect on CSF TAU (cerebro-spinal fluid - microtubule associated protein - tau), acute and chronic treatment ($400,000 - GCRC - General Clinical Research Center, component project)

Principal Investigator (7/1/2002 - 6/30/2003) Inhibition of Alzheimer neuropathology with lithium.  University of Kentucky, College of Medicine ($15,000)

Principal Investigator(s): John Wesson Ashford, MD, Nikolaos Tezapsidis (contact), PHD
Project Title: Leptin as a Therapy for Alzheimer's Disease, Grant Number: 2R44AG029670-03
Project Period: 04/03/2006 – 07/31/2012

Co-Investigator
04/84 - 08/89   NIH; "Emission Computed Tomography of Local Cerebral Functions"; (P.I.: D. Kuhl); $2,000,000: 15% time.
02/87 - 06/89   NIH; "Effects of Long Acting Anticholinesterases in Alzheimer's Disease"; (1 RO1 MKH 41821); (P.I.: R. E. Becker), $91,752: 10% time.
07/86 - 06/89   NIMH; "Clinical Training in Geriatric Mental Health"; (5 T24 MH 18449); (P.I.: V. Kumar), $211,537: 10% time.

10/87 - 06/88   Illinois Department of Public Health; "Human Chromosome 21-beta amyloid and D-21 S11 Genes in Familial and Non-Familial Alzheimer's Disease"; (P.I.: L. Maroun), $20,000: 5% time.
10/87 - 06/88   Illinois Department of Public Health; "Alzheimer's Disease-like Changes in a Hippocampal Cell Culture Model"; (P.I.: G. Brewer), $20,000: 5% time.
02/87 - 12/90   Illinois Department of Public Health; "Southern Illinois University School of Medicine's Regional Alzheimer's Disease Assistance Center"; (P.I.: R. Robertson), $3,100,000: 30% time.
1/93 - 4/94       Miles Laboratories: "Study of Metrifonate"; (P.I.: Pettigrew), 10% time
10/93 - 09/96   Geriatric Education Center Grant - NIA, $805,727; (P.I. Markesbery) 5% time
07/93 - 2002 Sub-contract from the Alzheimer's Disease Cooperative Study Group, Leon Thal, P.I., University of California, San Diego, Funded by National Institute of Aging,(Site P.I.: Schmitt)
     1) Instrument Protocol.
     2) Study of melatonin in Alzheimer's disease
     3) Study of estrogen in Alzheimer's disease
     4) Treatment of mild cognitive impairment
05/95 - 04/00  Alzheimer's Disease Research Center Clinical Core-NIA,$1,4 mil.;(P.I.: Markesbery - 10% time

1997 - 2000 Study of Ondansetron, Quintiles (P.I. Schmitt)

1998 - 2001 Study of memantine, MERZ (P.I. Schmitt)

DISSERTATION
1984 Ashford, J.W. Electrophysiology of visual encoding in the monkey. PhD Dissertation, Department of Neuroscience, UCLA, Chairman: J. Fuster.

PUBLICATIONS (peer-reviewed journals)

  1. 1972 Pascalon, A., Ashford, W., Dansereau, J. and Mouret, J. The effect of 6-Chlorotryptophan on sleep in the rat. Life Sciences. 11:893-903, Part 1.
  2. 1979 Ashford, J.W. and Ford, C.V. Use of MAO inhibitors in elderly patients. American Journal of Psychiatry, 136:1466-1467.
  3. 1980 Ashford, J.W., Schulz, S.C. and Walsh, G.O. Violent automatism in a partial complex seizure. Archives of Neurology, 37:120-122.
  4. 1981 Ashford, J.W., Soldinger, S., Schaeffer, J. Cochran, L. and Jarvik, L.F. Physostigmine and its effect on six patients with dementia. American Journal of Psychiatry, 138:829-830.
  5. 1982 Fuster, J.M., Willey, T.J., Riley, D.M. and Ashford, J.W. Effects of ethanol on visual evoked responses in monkeys performing a memory task. Electroencephalography and Clinical Neurophysiology, 53:621-633.
  6. 1985 Ashford, J.W., Coburn, K.L. and Fuster, J.M. The elgiloy microelectrode: fabrication techniques and characteristics. Journal of Neuroscience Methods. 14:247-252. 
  7. 1985 Ashford, J.W. and Fuster, J.M. Occipital and inferotemporal responses to visual signals in the monkey. Experimental neurology. 90:444-466.
  8. 1985 Ashford, J.W. and Jarvik, K.L. Alzheimer's disease: does neuron plasticity predispose to axonal neurofibrillary degeneration? New England Journal of Medicine. 5:388-389.
  9. 1987 Ashford, J.W., Rosenblatt, M.J., Bekian, C. and Hayes, T. The complete dementia evaluation: complications and complexities. The American Journal of Alzheimer's Care and Research. 9-15.
  10. 1988 Coburn, K.L., Ashford, J.W. and Moreno, M.A. Electrocortical mapping in a mixed AD-CVA patient. Brain Atlas Special Interest Society Newsletter, Touching Basis, 2:6-11.
  11. 1988 Kumar, V., Smith, R.C., Sherman, K.A., Ashford, W., Murphy, J., Giacobini, E. and Colliver, J. Cortisol responses to cholinergic drugs in Alzheimer's disease. International Journal of Clinical Pharmacology Therapy and Toxicology. 26:471-476.
  12. 1988 Small, G.W., Kuhl, D.E., Fujikawa, D.G. and Ashford, J.W. Clinical characterization of Alzheimer's disease: reliability of "age at onset" and a new descriptor, "age at shift". Journal of Geriatric Psychiatry and Neurology. 1:207-211.
  13. 1989 Small, G.W., Kuhl, D.E., Riege, W.H., Fujikawa, D.G., Ashford, J.W., Metter, E.J. and Mazziotta, J.C. Cerebral glucose metabolic patterns in Alzheimer's disease. Archives of General Psychiatry. 46:527-532.
  14. 1989 Parks, R.W., Crockett, D.J., Tuokko, H., Beattie, B.L., Ashford, J.W., Coburn, K.L., Zec, R.F., Becker, R.E., McGeer, P.L. and McGeer, E.G. Neuropsychological "systems efficiency" and positron emission tomography. Journal of Neuropsychiatry. 1:269-282.
  15. 1989 Ashford, J.W., Kolm, P., Colliver, J.A., Bekian, C. and Hsu, L.N. Alzheimer patient evaluation and the mini-mental state: item characteristic curve analysis. Journal of Gerontology. 44:139-146
  16. 1989 Ashford, J.W., Sherman, K.A. and Kumar, V. Advances in Alzheimer therapy: cholinesterase inhibitors. Neurobiology of Aging, 10:99-105.
  17. 1990 Coburn, K.L., Ashford, J.W. and Fuster, J.M. Visual response latencies in temporal lobe structures as a function of stimulus information load. Behavioral Neuroscience 104:62-73.
  18. 1990 Cohen, D., Paveza, G., Levy, P.S., Ashford, J.W., Brody, J.A., Eisdorfer, C., Gorelick, P., Hirschman, R., Luchins, D., Trozzolo, T. and Shaw, H. An Alzheimer's disease patient registry: the prototype Alzheimer collaborative team (PACT). Aging 2:312-316. 
  19. 1990 Cohen, D., Luchins, D., Eisdorfer, C., Paveza, G., Ashford, J.W. Gorelick, P., Hirschman, R., Freels, S., Levy, P., Semla, T. and Shaw H. Caring for relatives with Alzheimer's disease: The mental health risks to spouses, adult children, and other family caregivers. Behavior, Health and Aging 1:171-182.
  20. 1991 Parks, R.W., Coburn, K.L., Zec, R.F., Ashford, J.W., Crockett, D.J., Kuhn, M., Moreno, M.A., Rashid, A., Vicari, S. and Feldman, E. Electrocortical mapping, MRI, and neuropsychological measures: evidence of Alzheimer's disease in the presence of vascular lesions. Archives of Clinical Neuropsychology 6:393-408.
  21. 1991 Coburn, K.L., Ashford, J.W. and Moreno, M.A. Visual evoked potentials in dementia: selective delay of flash P2 in probable Alzheimer disease. Journal of Neuropsychiatry and Clinical Neuroscience 3:431-435.
  22. 1992 Hargrave, R. and Ashford, J.W. The use of MAO inhibitors in a patient with atypical depression and Parkinson's Disease. American Journal of Psychiatry. 149:1751-1752.
  23. 1992 Ashford, J.W., Kumar, V., Barringer, M., Becker, M., Bice, J., Ryan, N. and Vicari, S. Assessing Alzheimer severity with a global clinical scale. International Psychogeriatrics 4:55-74.
  24. 1992 Eisdorfer, C., Cohen, D., Paveza, G.J., Ashford, J.W., Luchins, D.J., Gorelick, P.B., Hirschman, R.S., Freels, S.A., Levy, P.S., Semla, T.P, and Shaw, H.A. An empirical evaluation of the global deterioration scale for staging Alzheimer's disease. American Journal of Psychiatry 149:190-194.
  25. 1992 Paveza, G.J., Cohen, D., Eisdorfer, C., Freels, S., Semla, T., Ashford, J.W., Gorelick, P., Hirschman, R., Luchins, D. and Levy, P. Severe family violence and Alzheimer's disease: Prevalence and risk factors. The Gerontologist 32:493-497.
  26. 199  Luchins, D.J., Hanrahan, P., Cohen, D., Eisdorfer, C., Paveza, G., Ashford, J.W., Gorelick, P., Hirschman, R., Freels, S., Levy, P., Shaw, H. Are there clinical differences between familial and non-familial Alzheimer's disease? American Journal of Psychiatry 149:1023-1027.
  27. 1992 Brewer, G.J. and Ashford, J.W. Elderly human serum stimulates Alzheimer markers in cultured hippocampal neurons. Journal of Neuroscience Research 33:355-369.
  28. 1992 Freels, S., Cohen, D., Eisdorfer, C., Paveza, G., Gorelick, P., Luchins, D.J., Hirschman, R., Ashford, J.W., Levy, P., Semla, T., and Shaw, H. Functional status and clinical findings in patients with Alzheimer's Disease. Journal of Gerontology 47(6):M177-M182. 
  29. 1993 Cohen, D., Eisdorfer, C., Gorelick, P., Paveza, G., Luchins, D.J., Freels, S., Ashford, J.W., Semla, T., Levy, P., Hirschman, R. Psychopathology associated with Alzheimer's disease and related disorders. Journal of Gerontology: Medical Sciences 48(6):M255-M260.
  30. 1993 Cohen, D., Eisdorfer, C., Gorelick, P., Luchins, D., Freels, S., Semla, T., Paveza, G., Shaw, H., Ashford, J.W. Sex differences in the psychiatric manifestations of Alzheimer's disease. Journal of the American Geriatric Society 41(3):229-232.
  31. 1993 Coburn, K.L., Ashford, J.W. and Moreno, M.A. Delayed late-components of visual global field-power in probable Alzheimer disease. Journal of Geriatric Psychiatry and Neurology 6:72-77.
  32. 1993 Semla, T.P., Cohen, D., Paveza, G., Eisdorfer, C., Gorelick, P., Luchins, D., Hirshman, R., Freels, S., Levy, P., Ashford, J.W. Drug use patterns in persons with Alzheimer's disease and related disorders living in the community. Journal of the American Geriatric Society 41:408-413.
  33. 1994 Ashford, J.W.: Meeting Report of: "Challenging Views of Alzheimer's disease", Cincinnati, Ohio, July 27-29, 2001. In: Expert Reviews in Neurotherapeutics, 1:7-10.
  34. 1994  Coburn, K.L., Ashford, J.W., & Moreno, M.A. Delayed late component of visual global field power in probable Alzheimer's disease. Parkinson/Alzheimer Digest, 5:23-24
  35. 1995 Smith, C.J., Lippiello, P.M. and Ashford, J.W. Smoking, Alzheimer's disease, and confounding with genes. Lancet, 345:1054.
  36. 1995 Ashford, J.W., Shan, M., Butler, S., Rajesekar, A. & Schmitt, F. "Temporal Quantification of Alzheimer's Disease Severity: 'Time Index" Model.'" Dementia, 6(5):269-280.
  37. 1995 Semla, T.P., Cohen, D., Freels, S., Paveza, G., Ashford, J.W., Gorelick, P., Luchins, D., & Eisdorfer, C. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease. Pharmacotherapy, 15(4):495-501.
  38. 1995 Mark, R.J., Ashford, J.W., Goodman, Y., and Mattson, M. P. Anticonvulsants Attenuate Amyloid ?-Peptide Neurotoxicity, Ca2+ Deregulation, and Cytoskeletal Pathology. Neurobiology of Aging, 16(2):187-198. 
  39. 1995 Semla, T.P., Cohen, D.C., Freels, S., Paveza, G.J., Ashford, J.W., et. al. Psychotropic Drug Use in Relation to Psychiatric Symptoms in Community-Living            Persons With Alzheimer's Disease. Pharmacotherapy, 15(4):495-501.
  40. 1996  Freels, S. Cohen, D. Semla, T. Paveza, G. Eisdorfer, C. Luchins, D. Ashford, J. W. Gorelick, P. Shaw, H. Levy, P. Predicting Survival in Patients With Alzheimer's Disease Living in the Community. Journal of Mental Health and Aging, 2(2):115-124.
  41. 1996 Butler, M., Ashford, J.W., and Snowdon, D.A. Age, Education, and Changes in the Mini-Mental State Exam Scores of Elderly Women. Journal of American Geratrics Society, 44:675-681.
  42. 1996 Ashford, J.W., Schmitt, Frederick A. and Kumar, Vinod. Diagnosis of Alzheimer's Disease. Psychiaric Annals, 26(5):262-268.
  43. 1996 Ashford, J.W., and Miller, T.W. Effect of Trazodone on Sleep in PTSD Patients." Journal of Contemporary Psychotherapy, 26(3):221-233.
  44. 1997 Geddes, J.W., Tekirian, T.L., Soultanian, N.S., Ashford, J.W., Davis, D. G., and Markesbery, W.R. Comparison of Neuropathologic Criteria for the Diagnosis of Alzheimer's Disease. Neurobiology of Aging, 18(S4):S99-S105.
  45. 1997 Sano, M., et. al. (Ashford, J. W., member of the Alzheimer's Disease Cooperative Study) A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease. The New England Journal of Medicine, 38(17):1216-1247.
  46. 1997  Schmitt, F.A., Ashford, J.W., Ernesto, C., Saxton, J., Schneider, L.S., Clark, C.M., Ferris, S.H., Mackell, J.A., Schafer, K., Thal, L.J., and the Alzheimer's Disease Cooperative Study. The Severe Impairment Battery: Concurrent Validity and the Assessment of Longitudinal Change in Alzheimer's Disease. Alzheimer Disease and Associated Disorders. 11(2):S51-S56.
  47. 1998  Pettigrew, L.C., Bieber, F., Lettieri, J., Wermeling, D.P., Schmitt, F.A., Tikhtman, A.J., Ashford, J.W., Smith, C.D., Wekstein, D.R., Markesbery, W.R., Orazem, J., Ruzicka, B.B., Mas, J., and Gulanski, B. A Study of the Pharmacokinetics, Pharmacodynamics and Safety of Metrifonate in Alzheimer's Disease Patients. Journal of Clinical Pharmacology. 38:236-245.
  48. 1998  Piecoro, L.T., Wermeling, D.P., Schmitt, F.A., Ashford, J.W. Seizures in patients receiving concommitant antimuscarinics and acetylcholinesterase inhibitor. Pharmacotherapy. 18:1129-1132.
  49. 1998  Ashford, J.W., Soultanian, N.S., Zhang, S.-X., Geddes, J.W. Neuropil threads are colinear with MAP2 immunostaining in neuronal dendrites of Alzheimer brain. Journal of Neuropathology and Experimental Neurology. 57:972-978.
  50. 1998  Shih, W.-J., Davis, D.G., Stipp, V., Ashford, J.W., Magoun, S. Bilateral perfusion defect/hypoperfusion in temporal and parietal regions on brain SPECT. Seminars in Nuclear Medicine. 28:192-193.
  51. 1998  Cummings, J.L., et al. (Ashford, J.W., member of metrifonate study group). Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology. 50:1214-1221.
  52. 1999  Shih, W.-J., Ashford, J.W., Stipp, V., Magoun, S.L. Coupal, J.J., Gross, K.K. Consecutive brain SPECT surface three-dimensional displays show progression of cerebral cortical abnormalities in Alzheimer's disease. Clinical Nuclear Medicine. 24:773-777.
  53. 2000  Ashford, J.W., Shih, W.-J., Coupal, J., Shetty, R., Schneider, A., Cool, C., Aleem, A., Stipp, V., Mendiondo, M.S., Schmitt, F.A. Single SPECT measures of cerebral cortical perfusion reflect "Time-Index" estimation of dementia severity in Alzheimer's disease. Journal of Nuclear Medicine. 41:57-64
  54. 2000  Mediondo, M.S., Ashford, J.W., Kryscio, R.J., Schmitt, F.A. Modeling mini-mental state exam changes in Alzheimer's disease. Statistics in Medicine. 19:1607-1616.
  55. 2000  Mulnard, R.A., et al for the Alzheimer's Disease Cooperative Study (Ashford, J.W., listed). Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. JAMA. 283:1007-1015.
  56. 2000  Schmitt, F.A., Davis, D.G., Wekstein D.R., Smith, C.D., Ashford, J.W., Markesbery, W.R. "Preclinical" AD revisited: Neuropathology of cognitively normal older adults. Neurology. 55:370-376.
  57. 2000  Shih, W.-J., Ashford, W., Davis, D.G., Stipp, V., Magoun, S. Bilateral perfusion defect/hypoperfusion in temporal and parietal regions on brain SPECT. Seminars in Nuclear Medicine. 28:192-193.
  58. 2001  Ashford, J.W., Schmitt, F.A. Modeling the time-course of Alzheimer dementia. Current Psychiatry Reports, 3:20-28.
  59. 2002   Goldstein L, Ashford JW, Busciglio J, Crutcher K, Gouras G, Kinoshita J, Mandelkow E, Sudol M. From here to there: AbetaPP as an axonal transport receptor--how could this explain neurodegeneration in AD. J Alzheimers Dis 5:483-9.
  60. 2002 Ashford, J.W., Mortimer, J.A. Non-familial Alzheimer's disease is mainly due to genetic factors.  Journal of Alzheimer's Disease.  4:1-9.
  61. 2002 Ashford, J.W.  ApoE4: Is it the absence of good or the presence of bad? Journal of Alzheimer's Disease.  4:141-3
  62. 2002 Schmitt, F.A., Cragar, D., Ashford, J.W., Reisberg, B, Ferris, S., Mobius, H.-J., Stoffler, A.  Measuring cognition in advanced Alzheimer's disease for clinical trials.  Journal of Neural Transmission [Suppl]. 62:135-148.
  63. 2002 Teter, B., Ashford, J.W. Neuroplasticity in Alzheimer's Disease.  Journal of Neuroscience Research. 70:402-437.
  64. 2003 Mendiondo, M.S, Ashford, J.W., Kryscio R.J., Schmitt, F.A. Designing a Brief Alzheimer Screen (BAS). J Alzheimers Dis. 2003 Oct;5(5):391-8.
  65. 2004 Yesavage, J.A., Sheikh, J., Noda, A., Murphy, G., O'Hara, R., Hierholzer, R., Battista, M., Ashford, J.W., Kraemer, H.C., Tinklenberg, J.  Use of a VA pharmacy database to screen for areas at high risk for disease: Parkinson's disease and exposure to pesticides. Journal of Geriatric Psychiatry Neurology. 17(1):36-8.
  66. 2004 Ashford, J.W. APOE Genotype effects on Alzheimer’s disease onset and epidemiology.  Journal of Molecular Neuroscience. 23(3) :155-163.
  67. 2004 Raber, J., Huang, Y., Ashford, J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiology of Aging 25(5):641-50.
  68. 2005 Ashford JW, Atwood CS, Blass JP, Bowen RL, Finch CE, Iqbal K, Joseph JA, Perry G. What is aging? What is its role in Alzheimer's disease? What can we do about it? J Alz Dis 7(3):247-53; discussion 255-62.
  69. 2006 Yesavage JA, Sheikh J, Noda A, Murphy G, O'hara R, Hierholzer R, Battista M, Ashford JW, Schneider B, Hoblyn J, Kraemer HC, Tinklenberg J.  Spatial test for agricultural pesticide "blow-in" effect on prevalence of Parkinson's disease.  Journal of Geriatric Psychiatry & Neurology 19(1):32-5.
  70. 2006 Ashford, J.W., Borson, S., O’Hara R, Dash P, Frank L, Robert P, Shankle WR, Tierney MC, Brodaty H, Schmitt FA, Kraemer HC, Buschke H. Should older adults be screened for dementia? Alzheimer’s & Dementia. 2(April): 76-85.
  71. 2006 Noda A, Kraemer HC, Taylor JL, Schneider B, Ashford JW, Yesavage JA. Strategies to reduce site differences in multisite studies: a case study of Alzheimer disease progression. Am J Geriatr Psychiatry 14:931-8.
  72. 2006 Ota KS, Friedman L, Ashford JW, Hernandez B, Penner AL, Stepp AM, Raam R, Yesavage JA. The Cost-Time Index: A new method for measuring the efficiencies of recruitment-resources in clinical trials. Contemp Clin Trials. 27L494-7.
  73. 2006 Schmitt FA, Mendiondo MS, Kryscio RJ, Ashford JW. A brief Alzheimer’s screen for clinical practice. Research Practice in Alzeimer’s Disease 11:1-4.
  74. 200  Ashford JW, Borson S, O’Hara R, Dash P, Frank L, Robert P, Shankle WR, Tierney MC, Brodaty H, Schmitt FA, Kraemer HC, Buschke H, Fillit H. Should older adults be screened for dementia? Screening for evidence of dementia is important! Alzheimer's and Dementia April;3:75-80..
  75. 2007 Ashford JW, Kraemer HC, Tinklenberg JR, O’Hara R, Taylor JL, Yesavage JA.  Statistical and pharmacoeconomic issues for dementia screening. Alzheimer's & Dementia April;3:126.
  76. 2007   Tinklenberg JR, Kraemer HC, Yaffe K, Ross L, Sheikh J, Ashford JW, Yesavage JA, Taylor JL. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? American Journal of Geriatric Psychiatry. Nov;15(11):953-60.
  77. 2008  Ashford JW, Borson S. Primary care screening for dementia and mild cognitive impairment. JAMA. Mar 12;299(10):1132-3.
  78. 2008 Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. Pharmacotherapy. Jul;28(7):875-82.
  79. 2008 Adamson MM, Landy KM, Duong S, Fox-Bosetti S, Ashford JW, Murphy GM, Weiner M, Taylor JL. Apolipoprotein E varepsilon4 influences on episodic recall and brain structures in aging pilots. Neurobiol Aging. Jun;31(6):1059-63.
  80. 2008 Ashford JW. Screening for Memory Disorder, Dementia, and Alzheimer's disease. Aging Health. 4(4):399-432
  81. 2008 Greco SJ, Sarkar S, Johnston JM, Zhu X, Su B, Smith MA, Casadesus G, Ashford JW, Tezapsidis N. Leptin reduces Alzheimer’s disease-related tau phosphorylation in 3 neuronal cells. Biochemical and Biophysical Research Communications. Nov 21;376(3):536-41.
  82. 2008 Ashford JW. Integration of EEG and brain imaging: advancing the understanding of neuro-cognitive dysfunction. J Alzheimers Dis. Nov;15(3):373-4.
  83. 2008 Yesavage JA, Friedman L, Ashford JW, Kraemer HC, Mumenthaler MS, Noda A, Hoblyn J. Acetylcholinesterase inhibitor in combination with cognitive training in older adults. J Gerontol B Psychol Sci Soc Sci. Sep;63(5):P288-94.
  84. 2009 Tezapsidis N, Smith MA, Ashford JW.  Central obesity and increased risk of dementia more than three decades later.  Neurology. 2009 Mar 17;72(11):1030-1.
  85. 2009 Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zhu X, Greco SK, Sarkar S. Leptin: A novel therapeutic strategy for Alzheimer’s disease. Journal of Alzheimer’s Disease. 16:1-10.
  86. 2009 Greco SJ, Sarkar S, Casadesus G, Zhu X, Smith MA, Ashford JW, Johnston JM, Tezapsidis N.  Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neuroscience Letters May 22;455(3):191-4.
  87. 2009 Rosen A, Zhang Y, Zhan W, Kasprisin A, Martinson S, Cheng J, Weiner M, Yesavage JA, Ashford JW. Mild traumatic brain injury from blast resulting in arcuate fasciculus damage diagnosed on DTI Tractography.  Military Medicine, Radiology Corner Nov; 174(11):v-vi.
  88. 2009  Halbauer J, Ashford JW,  Zeitzer JM, Adamson, MM, Lew HL, Yesavage JA. Neuropsychiatric diagnosis and management of chronic sequelae of war-related mild to moderate traumatic brain injury. Journal of Rehabilitation Research & Development. 46(6):757-796.
  89. 2010  Greco SJ, Bryan KJ, Sarkar S, Zhu X, Smith MA, Ashford JW, Johnston JM, Tezapsidis N, Casadesus G. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Disease, 19(4):1155-67.
  90. 2011  Ashford JW, Gere E, Bayley PJ. Measuring Memory in Large Group Settings Using a Continuous Recognition Test.  J Alzheimers Dis. 2011 Sep 9. 27(4):885-95.
  91. 2011  Greco SJ, Hamzelou A, Johnston JM, Smith MA, Ashford JW, Tezapsidis N. Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and β-amyloid in neurons. Biochem Biophys Res Commun. 414(1):170-174
  92. 2011 Ashford JW, Salehi A, Furst A, Bayley P, Frisoni GB, Jack CR Jr, Sabri O, Adamson MM, Coburn KL, Olichney J, Schuff N, Spielman D, Edland SD, Black S, Rosen A, Kennedy D, Weiner M, Perry G. Imaging the Alzheimer Brain. J Alzheimer’s Disease.  26(Sup 3):1-27.
  93. 2011 Ashford JW, Coburn KL, Rose TL, Bayley PJ.  The topography of P300 energy loss in aging and Alzheimer’s disease. Journal of Alzheimer’s Disease.  26(Sup 3):229-238.
  94. 2011 Ashford JW, Adamson MM, Beale T, La D, Hernandez B, Noda A, Rosen A, O’Hara R, Fairchild JK, Spielman D, Yesavage JA. Spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia.  J Alzheimer’s Disease. 26(Sup 3):331-336.
  95. 2011 Johnston JM, Greco SJ, Hamzelou A, Ashford JW, Tezapsidis N. Repositioning leptin as a therapy for Alzheimer's disease. Therapy.  Sep;8(5):481-490.
  96. 2012 Greco SJ, Hamzelou A, Johnston JM, Richardson S, Smith MA, Perry G, Ashford JW, Tezapsidis N. Isotyping the human TOMM40 variable-length polymorphism by gene amplification and restriction digest. Curr Alzheimer Res. 9(10):1168-73.
  97. 2013 Ashford JW, Bayley PJ. Retrogenesis: a model of dementia progression in Alzheimer's disease related to neuroplasticity. J Alzheimers Dis. 33(4):1191-3.
  98. 2013 Borson S, Frank L, Bayley PJ, Boustani M, Dean M, Lin PJ, McCarten JR, Morris JC, Salmon DP, Schmitt FA, Stefanacci RG, Mendiondo MS, Peschin S, Hall EJ, Fillit H, Ashford JW. Improving dementia care: the role of screening and detection of cognitive impairment. Alzheimers Dement. 9(2):151-9.
  99. 2013 Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, Dang V, Sanchez MM, De Miguel Z, Ashford JW, Salehi A. Ascending monoaminergic systems alterations in Alzheimer's disease; Translating basic science into clinical care. Neurosci Biobehav Rev. 37(8):1363-1379.
  100.  2013 Lazzeroni LC, Halbauer JD, Ashford JW, Noda A, Hernandez B, Azor V, Hozack N, Hasson N, Henderson VW, Yesavage JA, Tinklenberg JR. Memantine is Associated with Longer Survival than Donepezil in a Veterans Affairs Prescription Database, 1997 to 2008. J Alzheimer’s Dis. 36(4):791-8.
  101.  2013 Lange G, McAndrew L, Ashford JW, Reinhard M, Peterson M, Helmer DA. The War-Related Illness & Injury Study Center (WRIISC):   A multidisciplinary translational approach to the care of Veterans with Chronic Multi Symptom Illness. Military Medicine. 178(7):705-7.
  102.  2014 Johnston JM, Hu W, Fardo DW, Greco SJ, Perry G, Montine TJ, Trojanowski JQ, Shaw LM, Ashford JW, Tezapsidis N, For The Alzheimer's Disease Neuroimaging Initiative.  Low Plasma Leptin in Mild Cognitively Impaired/Alzheimer's disease ADNI1 subjects- gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res. 11(2):165-74
  103.  2014  Bayley PJ, Kong JY, Helmer DA, Schneiderman A, Roselli LA, Rosse SM, Jackson JA, Baldwin J, Isaac L, Nolasco M, Blackman MR, Reinhard MJ, Ashford JW, Chapman JC; MIND Study Group. Challenges to be overcome using population-based sampling methods to recruit veterans for a study of post-traumatic stress disorder and traumatic brain injury. BMC Med Res Methodol. 14(1):48.
  104. 2014 Dang V, Medina B, Das D, Moghadam S, Martin KJ, Lin B, Naik P, Patel D, Nosheny R, Ashford JW, Salehi A. Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome.  Biol Psychiatry. Feb 1;75(3):179-88.
  105.  2014 Rosen AC, Ashford JW, Perry G. Ethics review as a catalyst for progress. J Alzheimer’s Dis. 40(2):233-5.
  106.  2014 Adamson MM, Main K, Kong JY, Soman S, Furst A, Kinoshita K, Yesavage J, Ashford, JW. Integration of Clinical and Research Neuroimaging to Understand Traumatic Brain Injury in the Veteran Population. Fed Pract. 31(Suppl. June): 3S-7S.
  107.  2014 Taylor JL, Scanlon BK, Farrell M, Hernandez B, Adamson MM, Ashford JW, Noda A, Murphy GM, Weiner MW.  APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years. Neurobiol Aging. Nov;35(11):2479-85.
  108.  2014 Ashford JW, Furst AJ. Advancing brain imaging for Alzheimer's disease: integrating anatomic and physiologic measures. J Alzheimers Dis. 41(3):759-63
  109.  2015 Bayley PJ, Kong JY, Mendiondo M, Lazzeroni LC, Borson S, Buschke H, Dean M, Fillit H, Frank L, Schmitt FA, Peschin S, Finkel S, Austen M, Steinberg C, Ashford JW. Findings from the National Memory Screening Day program. J Am Geriatr Soc. Feb;63(2):309-14.
  110.  2015 Ashford JW, Mahoney L, Burkett T. A Role for Complementary and Integrative Medicine in Alzheimer's Disease Prevention.  J Alzheimers Dis. 2015;48(1):13-4.
  111.  2015 Tinklenberg JR, Kraemer HC, Yaffe K, O'Hara R, Ringman JM, Ashford JW, Yesavage JA, Taylor JL; California Alzheimer's Disease Centers. Donepezil treatment in ethnically diverse patients with Alzheimer disease. Am J Geriatr Psychiatry. Apr;23(4):384-90.
  112.  2015 Isaac L, Main KL, Soman S, Gotlib IH, Furst AJ, Kinoshita LM, Fairchild JK, Yesavage JA, Ashford JW, Bayley PJ, Adamson MM. The impact of depression on Veterans with PTSD and traumatic brain injury: a diffusion tensor imaging study. Biol Psychol. Feb;105:20-8.
  113.  2015 Ashford JW. Treatment of Alzheimer's Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions. J Alzheimers Dis. 47(1):149-56.
  114.  2016 Salehi A, Ashford JW, Mufson EJ. Editorial: The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective. Curr Alzheimer Res. 13(1):2-6. 
  115.  2016 Sheng T, Fairchild JK, Kong JY, Kinoshita LM, Cheng JJ, Yesavage JA, Helmer DA, Reinhard MJ, Ashford JW, Adamson MM. The influence of physical and mental health symptoms on Veterans’ functional health status J Rehab Res Dev. (In Press).

MULTI-SITE PARTICIPATING SCIENTIST
2010 – 2015 – 30 publications listed on PubMed for “Ashford W” referencing participation in ADNI (Alzheimer’s Disease Neuroimaging Initiative), the ADCS (Alzheimer’s Disease Cooperative Study), and the Citalopram Treatment for Alzheimer’s Disease Study (CTAD).
EDITED BOOK

Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M (Eds.) Handbook of Imaging the Alzheimer Brain. IOS Press, Amsterdam. 2011

BOOK CHAPTERS

  1. 1988  Ashford, J.W. and Bice, J.L. Choice reaction time in aged rhesus monkeys as a model of AD. In: Becker, R.E., Giacobini (eds) Advances in Alzheimer Therapy. Taylor-Francis, New York. 87-94
  2. 1988  Kumar, V., Murphy, J., Sherman, K.A., Ashford, J.W. and Markwell, S.J. Cognitive and neuroendocrine changes with physostigmine in Alzheimer's disease patients. In: Becker, R.E., Giacobini (eds) Advances in Alzheimer Therapy. Taylor-Francis, New York. 163-171
  3. 1988  Sherman, K.A., Kumar, V., Ashford, J.W., Murphy, J.W., Elble, R.J. and Giacobini, E. Effect of oral physostigmine in senile dementia patients: utility of blood cholinesterase inhibition and neuroendocrine responses to define pharmacokinetics and pharmacodynamics. In: Strong, R. et al, Central Nervous System Disorders of Aging: Clinical Intervention and Research. Raven Press, New York. 71-90
  4. 1989  Coburn, K.L., Ashford, J.W. and Moreno, M.A. VEP latency changes in Alzheimer's disease. In: Raz, I. (ed.) Neurological and Psychiatric Applications of Topographic Brain Mapping of EGG and Evoked Potentials. Bio-Logic, Chicago.
  5. 1993  Ashford, J.W.and Zec, R.F. Pharmacological Treatment in Alzheimer's Disease. In: Parks, R.W. and Zec, R.F. and Wilson, R.S. Neuropsychology of Alzheimer's Disease and Other Dementias. Oxford University Press.
  6. 1996  Ashford, J.W., Schmitt, F.A., Wermling, D., Bieber, F., Orazem, J., and Gulanski, B. Advantages of the "Time-Index" Method for Measurement of Alzheimer Dementia: Assessment of Metrifonate Benefit. In: Becker, R. and Giacobini, E. (Eds.) Alzheimer Disease: From Molecular Biology to Therapy. Birkhauser: Boston.
  7. 1996  Schmitt, F.A., Ashford, J.W., Ferris, S., Mackell, J., Saxton, J., Schneider, L., Clark, C., Ernesto, C., Schafer, K., and Thal, L. Severe Impairment Battery: A Potential Measure for AD Clinical Trials. In: Becker, R. and Giacobini, E. (Eds.) Alzheimer Disease: From Molecular Biology to Therapy. Birkhauser: Boston.
  8. 1998  Ashford, J.W., Mattson, M., Kumar, V. Neurobiological Systems Disrupted. In: Kumar, V. and Eisdorfer, C. (Eds.) Advances in the Diagnosis and Treatment of Alzheimer's Disease. Springer Publishing Company: New York, pp: 53-89.
  9. 1998  Ashford, J.W., Schmitt, F., Kumar, V. Diagnosis of Alzheimer's Disease. In: Kumar, V. and Eisdorfer, C. (Eds.) Advances in the Diagnosis and Treatment of Alzheimer's Disease. Springer Publishing Company: New York, pp: 111-151.
  10. 1998  Ashford, J.W., Coburn, K.L., Fuster, J.M. Functional Cognitive Networks in Primates. In: Parks, R.W. and Levine, D.S. Fundamentals of Neural Networks: Neuropsychology and Cognitive Neuroscience. The MIT Press: Cambridge, Mass, pp: 33-60.
  11. 2008 Gallagher-Thompson, D., Lonergan, K.H., Holland, J., China, D., Ashford, J.W. Supporting Family Caregivers. In: Lipton AM, Weiner MF, editors. American Psychiatric Publishing Textbook of Alzheimer's Disease and Other Dementias: The App Textbook of Geriatric Psychiatry Diagnostic Issues in Dementia. Arlington, VA: American Psychiatric Publishing; pp:353-366.
  12. 2011 Ashford JW, Salehi A, Furst A, Bayley P.  Imaging the Alzheimer Brain: The Pathology and Pathophysiological Bases of Alzheimer’s Disease: Implications for Advancing Diagnostic Imaging. In: Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M (Eds.) Handbook of Imaging the Alzheimer Brain. IOS Press, Amsterdam.  Pages 3-10.
  13. 2011 Ashford JW, Coburn KL, Rose TL, Bayley PJ.  The topography of P300 energy loss in aging and Alzheimer’s disease. In: Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M (Eds.) Handbook of Imaging the Alzheimer Brain. IOS Press, Amsterdam.  Pages 435-444.
  14. 2011  Ashford JW, Adamson MM, Beale T, La D, Hernandez B, Noda A, Rosen A, O’Hara R, Fairchild JK, Spielman D, Yesavage JA. Spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia  In: Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M (Eds.) Handbook of Imaging the Alzheimer Brain. IOS Press, Amsterdam.  Pages 599-604.
  15. 2014  Johnston JM, Perry G, Ashford JW, Tezapsidis N. Leptin in Alzheimer’s Disease and Other Cognitive Disorders and Association with Underlying Lipid Abnormalities.  In: Blum EL. Leptin: Biosynthesis, Functions and Clinical Significiance. Nova Science Publishers, Inc., Hauppauge, NY.  Pages 1 – 15.

NATIONAL COURSES / ORGANIZED SYMPOSIUMS

  1. 1998  Kumar, V., Ashford, J. W., Krasuski, J. Advances in Diagnosis and Management of Alzheimer's Disease in Psychiatric Practice. American Psychiatric Association Annual Meeting, Toronto, Canada.
  2. 2001  Ashford, J. W., Walsh, J., Farlow, M., Murphy, G., Gallagher-Thompson, D., Coon, D. Apolipoprotein-E (APO-E) genotype in predicting Alzheimer's disease. American Association of Geriatric Psychiatry, San Francisco.
  3. 2002  Ashford, J.W.  Neurological and Medical Aspects - Critical Elements in Geriatric Psychiatry (Geriatric Psychiatry Board Review Course, invited faculty).  American Association of Geriatric Psychiatry.  Orlando
  4. 2003  Ashford, J.W. (organizer), Schmitt, F.A., Boorson, S, Buschke, H., Dash, P., Mendiondo, M, Kraemer, H.  Designing brief Alzheimer screening tests for use in general medical practice.  American Association of Geriatric Psychiatry, Honolulu (symposium, 5/3).
  5. 2003  Raskind, M., Ashford, J.W. (organizer) Schmitt, F.A., Crane, P., van Belle, G., Geldmacher, D.  Measuring cognitive dysfunction in Alzheimer's disease.  American Association of Geriatric Psychiatry, Honolulu (symposium, 5/4).
  6. 2003  Ashford, JW (organizer), Schmitt, F, Borson, S, Buschke, H, Mendiondo, M, Tornatore JB, Kraemer HC.  Diverse approaches to Alzheimer screening.  American Psychiatry Association, San Francisco (symposium, 5/20).
  7. 2003 Ashford, JW (organizer), Schmitt, F. (co-chair), Borson, S, Buschke, H., Brodaty, H.  Developing approaches to Alzheimer Screening.  International Psychogeriatric Association, Chicago (symposium, 8/19).
  8. 2005 Ashford, JW, Tornatore, J (organizers) Alzheimer’s Asscociation
  9. 2005 O’Hara, R, Ashford, JW (organizers) Dementia scrrening. International Psychogeriatric Association
  10. 2007 O’Hara, R, Ashford, JW (organizers) Dementia Screening. American Association for Geriatric Psychiatric Annual meeting, New Orleans.
  11. 2008 Ashford (organizer); JW, Frank, L; Borson, Soo; Steffens, D. Dementia Screening in Clinical and Community Settings. American Association for Geriatric Psychiatric Annual meeting, Orlando, FL.
  12. 2009 – 2013 – numerous – not logged.
  13. 2008 – 2014 – numerous presentations, Webinars, professional communications organized in role as Director of the California site of the War Related Illness and Injury Study Center for the Veteran’s Affairs Department of Public Health

PUBLISHED ABSTRACTS AND INTERNATIONAL / NATIONAL PRESENTATIONS

  1. 1979 Blumenthal, M.D. and Ashford, J.W. et al. Psychogeriatric Services: transcontinental views. American Psychiatric Association, Annual Meeting, Chicago, IL.
  2. 1980 Strauss, G.D., Yager, J., Liston, E., Ashford, J.W., Gales, M., and Strauss, G.E. Testing psychiatric knowledge with in-house exams. American Psychiatric Association, Annual Meeting, San Francisco, CA.
  3. 1980 Schulte, J.L., and Ashford, J.W. et al. Mentally ill offender: Treatment issues in California. American Psychiatric Association, Annual Meeting, San Francisco, CA.
  4. 1980 Fuster, J.M., Willey, T.J., Riley, D.M. and Ashford, J.W. Alcohol effects on Neuroelectric activity and behavior of monkeys in a cognitive task. Society for Neuroscience: Tenth Annual Meeting.
  5. 1983 Ashford, J.W., and Fuster, J.M. Occipital and inferotemporal response to photic stimuli in the monkey performing a cognitive task. Society for Neuroscience: Thirteenth Annual Meeting, Boston, MA.
  6. 1985 Kuhl, D.E. Metter, E.J., Benson, D.F. and Ashford, J.W., et al. Similarities of cerebral glucose metabolism in Alzheimer's and Parkinsonian dementia, Brain Conference, Sweden.
  7. 1985 Kuhl, D.E., Metter, J., Benson, D.F., Ashford, J.W., Riege, W.H., Fujikawa, D.G., Markham, C.H., Mazziotta, J.C., Maltese, A. and Dorsey, D.A. Similarities of cerebral glucose metabolism in Alzheimer's and Parkinsonian dementia: Journal of Cerebral Blood Fl. Met. 5.
  8. 1985 Ashford, J.W., Rosenblatt, M.J., Bekian, C. and Hayes, T. Complications in the complete dementia evaluation: complications and complexities, American Psychiatric Association Annual Meeting, Washington, D.C.
  9. 1986 Ashford, J.W., Moffitt, T.E., and Bekian, C. Dementia staging: utility of MMS and ADL scales. Midwest Neurobiology Meeting, Springfield, IL.
  10. 1986 Ashford, J.W., Sherman, K.A., Elble, R.J., Jess, J., Larson, L.S., Rey, P., Higgins, C., Best, S., Woodruff, E.M. and Mcllhany, M. Physostigmine effect on human memory and plasma cholinesterase. Midwest Neurobiology Meeting, Springfield, IL.
  11. 1986 Sherman, K.A., Ashford, J.W., Elble, R.J., Hess, J. and Kumar, V. Effect of oral physostigmine in senile dementia patients. Fifth Annual Symposium on Geriatrics and Gerontology, St. Louis.
  12. 1986 Ashford, J.W., Elble, R., Sherman, K., Hess, J., Best, S. and Higgins, C. Physostigmine: memory vs plasma cholinesterase. American Psychiatric Association Annual Meeting, Washington, D.C.
  13. 1986 Sherman, K.A., Ashford, J.W., Elble, R.J., Hess, J., Mcllhany, Kumar, V., Becker, R.E., Giacobini, E. Inhibition of blood cholinesterase after oral physostigmine in Alzheimer patients. Society of Neuroscience.
  14. 1986 Sherman, K.A., Elble, R.J. Ashford, J.W., and Hess, J. Predicting response to physostigmine in senile dementia patients: inhibition of plasma or red blood cell cholinesterase. American Geriatric Society 43rd Annual Meeting, Chicago, IL.
  15. 1986 Ashford, J.W., Hsu, L.N., Becker, M., Kumar, V. and Bekian, C. Mini mental status and activities of daily living: cross validation by scalogram and item analysis techniques. Gerontological Society of America, The Gerontologist, Chicago, IL. 
  16. 1987 Sherman, K.A., Kumar, V., Ashford, J.W. and Murphy, J. Neuroendocrine response to physostigmine in senile dementia patients, Midwest Neurobiology Meeting, Springfield, IL.
  17. 1987 Giacobini, E., Ashford, J.W., Becker, R.E., Elble, R.J. and Sherman, K.A. Are there cholinergic markers for Alzheimer's disease? Winter Conference on Brain Res, Vail, CO.
  18. 1987 Ashford, J.W., Becker, R., and Dettling, R. Frontal system dementia in late schizophrenia. American Psychiatric Association, Annual Meeting.
  19. 1987 Small, G., Kuhl, D.E., Riege, W.H., Ashford, J.W. and Fujikawa, D.G. Diagnosis of Alzheimer subtypes with PET scan, American Psychiatric Association, Annual Meeting.
  20. 1987 Ashford, J.W. Physostigmine treatment of Alzheimer patients' memory vs. plasma cholinesterase. International Psychogeriatric Association, Third Congress, Chicago, IL.
  21. 1987 Small, G., Kuhl, D., Riege, W., Fujikawa, D., Ashford, W, Metter, J. and Mazziotta, J. Local cerebral metabolic differences in subgroups of Alzheimer disease. International Psychogeriatric Association, Third Congress, Chicago, IL.
  22. 1987 Kuhl, D.E., Small, G.W., Riege, W.H., Fujikawa, D.G., Metter, E.J., Benson, D.F., Ashford, J.W., Mazziotta, J.C., Maltese, A. and Dorsey, D.A. Cerebral metabolic patterns before the diagnosis of probable Alzheimer's disease. 13th International Symposium on Cerebral Blood Flow and Metabolism, Montreal, Canada.
  23. 1987 Kuhl, D.E., Small, G.W., Riege, W.H., Fujikawa, D.G., Metter, E.J., Benson, D.F., Ashford, J.W., Mazziotta, J.C., Maltese, A. and Dorsey, D.A. Cerebral metabolic patterns before the diagnosis of probable Alzheimer's disease. 13th International Symposium on Cerebral Blood Flow and Metabolism. Toronto, Canada.
  24. 1987 Ashford, J.W., Kumar, V., Becker, M., Barringer, M. and Vicari, S. Measuring Alzheimer progression: increasing precision using MMS-Ex: ADL's; CDR-M. Geriatric Society of America, Annual Meeting, Washington, D.C. The Gerontologist. 
  25. 1987 Ashford, J.W. and Bice, J. Scopolamine effect on choice reaction time in the monkey. Society for Neuroscience, Annual Meeting.
  26. 1987 Woodward, S.H., Brown, W.S., Marsh, J.T., Ashford, J.W., Winter, J. and Larue, A. P300 and CT-scan: their combined efficacy in dementia diagnosis. Gerontological Society of American, Annual Meeting, Washington, D.C. The Gerontologist.
  27. 1987 Kumar, V., Ashford, J.W. and Bekian, C. Measuring depression in Alzheimer patients. Gerontological Society of America, Annual Meeting, Washington, D.C. The Gerontologist.
  28. 1987 Kuhl, D.E., Small, G.W., Riege, W.H., Fujikawa, D.G., Metter, E.J., Benson, D.F., Ashford, J.W., Mazziotta, J.C., Maltese, A. and Dorsey, D.A. Abnormal PET-FDG scans in early Alzheimer's disease. Journal of Nuclear Medicine.
  29. 1988 Ashford, J.W., Kumar, V., Becker, M., Barringer, M. and Vicari, S. Measuring Alzheimer Progression: increasing precision using MMS-Ex: ADL's;CDR-M. Governor's Conference on Long Term Care, Chicago, IL.
  30. 1988 Ashford, J.W. and Bice, J. Choice reaction time in aged rhesus monkeys as a model of AD. Presented at an International Conference: Advances in Alzheimer's Therapy, Springfield, IL.
  31. 1988 Coburn, K.L., Ashford, J.W. and Moreno, M. Evoked potential changes reflect cholinergic cell loss. Presented at an International Conference: Advances in Alzheimer Therapy, Springfield, IL.
  32. 1988 Maroun, L.E., Yao, X., Ryan, N. and Ashford, J.W. Can RFLP analysis discriminate between familial and sporadic Alzheimer's disease? Presented at an International Conference: Advance in Alzheimer Therapy, Springfield, IL.
  33. 1989 Prohaska, T., Ashford, W., Brody, J., Eisdorfer, C., Gorelich, P., Hirschfeld, R., Levy, P., Luchins, P., Paveza, G., Trozzolo, T. and Cohen, P. Concomitant presenting problems of dementia at time of diagnosis. XIV International Congress of Gerontology, Acapulco, Mexico. 
  34. 1989 Paveza, J., Ashford, W., Brody, J., Eisdorfer, C., Gorelich, P., Hirschfeld, R., Levy, P., Lew, R., Luchins, D., Prohaska, T. and Cohen, D. Demographic characteristics of dementia patients from a three state registry and its implications for community care. XIV International Congress of Gerontology, Acapulco, Mexico.
  35. 1989 Bice, J., Edwards, H. and Ashford, J.W. Reaction time changes with aging in the monkey. Society for Neuroscience, Phoenix, AZ.
  36. 1989 Ashford, W., Bice, J., Vicari, S. and Feldman, E. Simple choice reaction vs Alzheimer severity. Gerontology Society of American, Minneapolis, MN.
  37. 1989 Cohen, P., Ashford, J.W., Gorelich, P., Eisdorfer, C., Luchins, D., Paveza, G., Hirschman, R., Levy, P. and Brody, J. A large scale prototype Alzheimer's disease patient registry. Gerontological Society of America, Minneapolis, MN.
  38. 1989 Coburn, K.L., Parks, R.W. and Ashford, J.W. The P300 in dementia: divergent physiological and behavioral changes. National Academy of Neuropsychologist.
  39. 1989 Parks, R.W., Coburn, K.L., Zec, R.F., Ashford, J.W., Moreno, M.A., Vicari, S., Feldman, S. and Dodrill, K. Electrocortical mapping in Alzheimer's disease with vascular lesions. International Neuropsychological Society.
  40. 1989 Brewer, G.J., Domino, L. and Ashford, J.W. Alzheimer-like pathology induced by human serum in cultured hippocampal neurons. Society for Neuroscience, Phoenix, AZ.
  41. 1989 Bice, J., Edwards, H. and Ashford, J.W. Reaction time changes with aging in the monkey. Society for Neuroscience, Phoenix, AZ.
  42. 1990 Ashford, J.W., Rashid, A., Lawrence, D., Calache, M., Bice, J., Evans, G. and Anderson, D. AD Pathology: quantitation by MRI? Society for Neuroscience, St. Louis, MO.
  43. 1990 Coburn, K.L. and Ashford, J.W. Visual evoked potential components in dementia: selective delay of flash P2 in probable Alzheimer's disease, 6th International Conference of Alzheimer Disease International, Mexico City, Mexico. 
  44. 1990 Brewer, G.J., Miksanek, B.K. and Ashford, J.W. Quantitative immunoreactivity of Alzheimer-like antigens increased by elderly human serum treatment of cultured neurons. Society for Neuroscience, St. Louis, MO.
  45. 1990 Paveza, G.J., Cohen, D., Ashford, W., Brody, J., Eisdorfer, C., Hirschman, R., Luchins, D., Shaw, H. and Trozzolo, T. The developing of a peripheral marker for the diagnosis of Alzheimer's disease, 6th International Conference of Alzheimer Disease International, Mexico City, Mexico.
  46. 1990 Cohen, D., Paveza, G., Eisdorfer, C., Gorelich, P., Luchins, D., Hirschman, R. and Ashford, W. Morbidity and co-morbidity in patients with Alzheimer's disease (AD): results from a large scale patient registry, 6th International Conference of Alzheimer Disease International, Mexico City, Mexico.
  47. 1990 Cohen, D., Paveza, G., Eisdorfer, C., Gorelich, P., Luchines, D., Hirschman, R. and Ashford W. The developing of a peripheral marker for the diagnosis of Alzheimer's disease, 6th International Conference of Alzheimer Disease International, Mexico City, Mexico.
  48. 1990 Cohen, D., Paveza, G., Eisdorfer, C., Gorelich, P., Luchins, D., Hirschman, R. and Ashford, W. Morbidity and co-morbidity in patients with Alzheimer's disease (AD): results from a large scale patient registry, Gerontological Society of America, Boston, MA.
  49. 1990 Eisdorfer, C., Cohen, D, Ashford, W., Luchins, D., Paveza, G., Brody, J., Hirschman, R. and Gorelich, P. An empirical challenge to the validity of the global deterioration scale to stage Alzheimer's disease, Gerontological Society of America, Boston, MA, The Gerontologist, 30, #138, pp. 156a.
  50. 1990 Paveza, G.J., Cohen, D., Ashford, W., Brody, J., Eisdorfer, C., Hirschman, R., Luchins, D., Shaw, H. and Trozzolo, T. Violence in families with an Alzheimer patient, Gerontological Society of America, Boston, MA, the Gerontologist, 30, #122, pp. 147a.
  51. 1991 Ashford, J.W., Edwards, H. Memory in the monkey: an automated paradigm and the effect of nicotine. Society for Neuroscience, New Orleans, LA. 
  52. 1991 Coburn, K.L., Ashford, J.W., Moreno, M.A. Delayed late component of visual global field power in probable Alzheimer's disease. Society for Neuroscience, New Orleans, LA.
  53. 1992 Coburn, K.L. and Ashford, J.W. Delayed late VEP component in Alzheimer's disease. International Society for Brain Electromagnetic Topography, 3rd International Congress, Amsterdam, Netherlands.
  54. 1992 Coburn, K.L., Ashford, J.W., Zec, R.F. Uses of brain electrical activity mapping in the detection of Alzheimer's disease in the presence of vascular lesions. KNAW, EBBS workshop on Functioning Brain Imaging, Amsterdam, Netherlands.
  55. 1992 Ashford, J.W., Coburn, V.L., Yamashita, K. P300 Power Loss in Aging and Alzheimer's Disease. Society for Neuroscience, #306.20, Anaheim, CA.
  56. 1993 Mattson, M.P., Cheng, B., Goodman, Y., Smith-Swintosky, V.L., Ashford, J.W., Oeltgen, J. Mimicking the neuroprotective mechanism of growth factor action with low molecular weight agents. Society for Neuroscience, Washington, D.C.
  57. 1993 Mark, R., Ashford, J.W., Goodman, Y., and Mattson, M.P. Valproic Acid Attenuates Excitotoxicity and Neurofibrillary Tangle-like Antigenic Changes in Hippocampal Neurons. Society for Neuroscience, Washington, D.C.
    v1994 Ashford, J.W., Shan, M., Butler, S., Rajesekar, A., Schmitt, F.A. Temporal quantification of Alzheimer's disease severity. Fourth International Conference on Alzheimer's Disease and Related Disorders, Minneapolis, Minnesota.
  58. 1994 Pettigrew, L.C., Smith, C.D., Schmitt, F.A., Wermeling, D., Tikhtman, A.J., Doshi, N., Ashford, J.W., and Gulanski, B. Cerebral energy metabolism and cognitive performance in Alzheimer's disease. American Association of Neurology.
    v1994 Ashford, J.W. Non-pharmacological treatment of Alzheimer's disease patients. American Psychiatric Association, Philadelphia, PA.
  59. 1996 Ashford, J.W. Advantages of the "Time-Index" Method for Measurement of Alzheimer Dementia: Assessment of Metrifonate Benefit. Fourth International Nice/Springfield Symposium on Advances in Alzhemier Therapy, Nice, France. 
  60. 1996 Schmitt, F.A., Ashford, J.W., Ferris, S., Mackell, J., Saxton, J., Schneider, L., Clark, C., Ernesto, C., Schafer and Thal, L. Severe Impairment Battery: A Potential Measure for AD Clinical Trials. Fourth International Nice/Springfield Symposium on Advances in Alzhemier Therapy, Nice, France.
  61. 1996 Tekirian, T.L., Snowdon, D.A., Racke D., Riley, K.P., Davis, D.G., Ashford, J.W., Soultanian, N.S., Markesbery, W.R., and Geddes, J.W. Entorhinal Cortex Pathology and Cognitive Performance in Aging and Alzheimer's Disease: Findings From the Nun Study. Society for Neurosciences, Washington, D.C.
  62. 1996 Dutton, K., Pace, S., Cook, C., Sickman, J., Fowler, J., Ashford, J.W., and Sebastian, J. "Advanced Practice Nurse Management for Chronically Ill Older Veterans". Third International Conference on Long Term Care Case Manainging, "Bridging the Many Worlds of Case Management", American Society on Aging in San Diego, CA.      .
  63. 1997 Ashford, J.W.,Shih, W.J., Coupal, J., Shetty, R., Schneider, A., Cool, C., Stipp, V., Aleem, A., and Schmitt, F.A. "Brain Spect Versus Dementia Severity in Alzhimer's Disease. 1997 Annual Meeting Society for Neuroscience, New Orleans, Louisiana. 
  64. 1997  Shih, W.J., Ashford, J.W., Stipp, V., Magoun, S.L., Coupal, J.J., Gross, K.K. Consecutive Brain SPECT Surface Three Dimensional Displays Show Progression of Cerebral Cortical Abnormalities in Alzheimer's Disease. American Association of Physicists in Medicine, Chicago, Illinois.
  65. 1997  Coupal, J.J., Shih, W.J., Ashford, J.W. Refrigerated-Saline Reconstitution of Freeze-Dried ECD: An Easy First Step for Long-Term Storage of ECD Solution. American Association of Physicists in Medicine, Chicago, Illinois.
  66. 1998  Mendiondo, M.S., Ashford, J.W., Kryscio, R.J., Schmitt, F.A. Modeling mini-mental state exam changes in Alzheimer's disease. Statistics in Alzheimer's Disease. Lexington, Kentucky.
  67. 1998  Ashford, J.W., Shih, W.-J., Mendiondo, M., Stipp, V., Coupal, J.J., Aleem, A., Aleem, B., Schmitt, F.A. Alzheimer's disease and SPECT: 3-dimensional brain surface displays (BSD's) reflect dementia severity, while consecutive studies show progression of individual abnormalities. Annual Meeting, Society for Neuroscience, Los Angeles, CA.
  68. 1999  Ashford, J.W., Shih, W.-J. Gulf War veterans with cortical perfusion defects on 3-D SPECT: A series of 10 cases. 1999 Annual Meeting, Society for Neuroscience, Miami, FL.
  69. 2000  Ashford, J.W., Reisberg, B., Yesavage, J., Stern, Y., Mungas, D., Modeling longitudinal changes and time factors in Alzheimer's disease: Technology to improve patient evaluation and treatment. 13th Annual Meeting, American Association for Geriatric Psychiatry, Miami, FL.
  70. 2000  Shih, W.-J., Ashford, J.W. Cerebral cortical perfusion abnormalities on brain SPECT in Gulf War veterans. 2000 Annual Meeting of the American Roentgen Ray Society, Washington, D.C.
  71. 2001  Ashford, J.W., Mendiondo, M.S., Kryscio, R.J., Schmitt, F.A. A Minute Alzheimer Screen. International Psychogeriatrics Association Meeting, Nice, France.
  72. 2002  Ashford, J.W., Mendiondo, M.S., Kryscio, R.J., Schmitt, F.A. Designing a Brief Alzheimer Screen, American Association of Geriatric Psychiatry, Orlando, FL.
  73. 2002  Ashford, J.W., Mendiondo, M.S., Kryscio, R.J., Schmitt, F.A. Designing a Brief Alzheimer Screen.  Statistics In Alzheimer's Disease.  Lexington, KY
  74. 2002  Ashford, J.W., Kindy, M., Shih, W.-J., Cool, C., Aleem, B., Cobb, L., Tsanatos, D. Age of onset of Alzheimer’s disease is earlier in patients with an APOE e4 allele.  Annual Meeting, Society for Neuroscience, Orlando, Fl
  75. 2003 Goldstein L, Ashford JW, Busciglio J, Crutcher K, Gouras G, Kinoshita J, Mandelkow E, Sudol M. Live discussion. From here to there: AbetaPP as an axonal transport receptor--how could this explain neurodegeneration in AD. 15 July 2002. Journal of Alzheimers Disease. 2003 Dec;5(6):483-9.
  76. 2003  Xiong, S., Xie1, C., Lovell, M.A.1,3; Markesbery, W.R., Ashford,  J.W., Gallicchio, V.S. Lithium inhibits GSK-3 mediated hyperphosphorylation of tau in the hippocampus of starved mice.  Annual Meeting, Society for Neuroscience, New Orleans, LA.  Nov. 12, #840.24.
  77. 2004 – present: numerous presentations not logged

LOCAL/STATE PRESENTATIONS

  1. 1991 "The Temporal Lobe and Perception of Psychic Trauma." 17th Annual Mid-winter Program in Contuing Medical Education for Psychiatrists. Lake Tahoe, CA.
  2. 1993 "Alzheimer's Disease: Can Anticonvulsants Stop the Pathology?" Kentucky Psychiatric Association, Covington, KY.
  3. 1994 "Assessing the Mental Status of the Elderly Patient," the 25th Family Medicine and Primary Care Review, University of Kentucky, Lexington, KY.
  4. 1996 Tekirian, T.L., Snowdon, D.A., Racke D., Riley, K.P., Davis, D.G., Ashford, J.W., Soultanian, N.S., Markesbery, W.R., and Geddes, J.W. Entorhinal Cortex Pathology and Cognitive Performance in Aging and Alzheimer's Disease: Findings From the Nun Study. Sanders-Brown Alzheimer's Disease Research Center & Department of Anatomy and Neurobiology, Lexington, Kentucky.
  5. 2001 "Advances in Alzheimer's Disease" University of Louisville, Symposium on Advances in Psychopharmacology, in conjunction with the Kentucky Psychiatric Association meeting (invited).
  6. 2002  Alzheimer's Disease.  (keynote address) Kentucky Psychiatric Association, Annual Meeting (9/24/2002).
  7. 2003 – present: numerous presentations, not logged